August 8, 2007
Renowned Cancer Drug Researcher Chris Takimoto, M.D., Ph.D., Joins South Texas Accelerated Research Therapeutics
Chris H. M. Takimoto, M.D., Ph.D., an internationally recognized leader in the development of new anti-cancer drugs, has been named director of pharmacology at South Texas Accelerated Research Therapeutics (START).
Dr. Takimoto comes to START from the Cancer Therapy & Research Center's Institute for Drug Development, where he was pharmacology director and held the Zachry Chair of Translational Research.
"Chris Takimoto brings with him a depth of clinical research experience and expertise with anti-cancer treatments that would be difficult to match," Dr. Tolcher said. "With Dr. Takimoto at START, I am confident that San Antonio will continue to lead the world in the area of Phase 1 oncology clinical trials."
Dr. Takimoto is a medical oncologist and a clinical investigator who is certified by the American Board of Internal Medicine in medical oncology and board eligible in clinical pharmacology.
He also is a clinical associate professor in the Medical Oncology Division of the University of Texas Health Science Center at San Antonio.
He completed medical school at Yale University School of Medicine. His post-graduate work was completed at University of California, San Francisco, the National Cancer Institute and Uniformed Services University of the Health Sciences. In addition to anti-cancer drug development, Dr. Takimoto's clinical interests include gastrointestinal malignancies.
Dr. Takimoto's work is featured in several textbooks for which he has written chapters.
He has published over 120 peer-reviewed articles, book chapters, editorials, and reviews in medical and scientific journals including the Journal of the National Cancer Institute, Journal of Clinical Oncology, Clinical Cancer Research, and Nature Clinical Practice Oncology. He has been a member of the editorial boards of the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Investigational New Drugs, and Current Problems in Cancer, among others. In addition, he has served on a number of advisory panels for organizations including the U.S. Food and Drug Administration, the National Cancer Institute, the American Society for Clinical Oncology and the American Association for Cancer Research.
START is affiliated with South Texas Oncology & Hematology, which has offices in several locations in the San Antonio area, and is building a 120,000-square-foot, comprehensive cancer center in San Antonio's South Texas Medical Center.
STOH will occupy 90,000 square feet of the new building, scheduled to open in July 2008 at the intersection of Medical and Ewing Halsell Drives. START will occupy 20,000 square feet. A radiology center will have about 10,000 square feet of space. The center also will feature a 660-space parking garage.
STOH and START physicians are known worldwide for their extensive experience in Phase I clinical trials, including trials of many of the leading cancer drugs on the market. Their numerous ongoing research affiliations include their work with the Pancreatic Cancer Research Team, which also involves world-class institutions such as the Mayo Clinic, Johns Hopkins University, Translational Oncology Research International (TORI, associated with Dennis Slamon and others at the University of California at Los Angeles), the Sarah Cannon Cancer Center in Nashville, Tenn., and Translational Genomics (TGEN) in Phoenix, Ariz.
More information about South Texas Oncology & Hematology is available online at www.stoh.com/.